Company & Sponsor Intelligence

Celgene

Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.

Request enterprise analysis →

Indexed trials4

Recruiting0

Completed3

Countries1

Therapeutic footprint

multiple_sclerosis

Indexed studies

NCT02294058Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)
multiple_sclerosis · United StatesPHASE3

NCT02797015Pharmacokinetics and Pharmacodynamics Study of RPC1063 in RMS
multiple_sclerosis · United StatesPHASE1

NCT02576717A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
multiple_sclerosis · United StatesPHASE3

NCT04140305Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063)
multiple_sclerosis · United StatesPHASE3

Intelligence layer updated: 2026-10-14 06:11:28.884102+00:00

Enterprise intelligence

Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.

Request comparative intelligence →